Esperion Therapeutics, Inc. (ESPR) has Current Market Capitalizaion of $534 Million

Posted March 21, 2017

Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Zacks Investment Research upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, March 2nd. The company has an average rating of "Hold" and a consensus target price of $28.24.

Esperion Therapeutics, Inc. closed its last trading session at $29.65 with the loss of -20.17%.

The share price of Edge Therapeutics, Inc. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.24) by $0.05.

10/26/2015 - JMP Securities began new coverage on Edge Therapeutics, Inc. giving the company a "market outperform" rating.

Several sell side analysts reviewed their recommendations on Juno Therapeutics Inc. They now have a United States dollars 18 price target on the stock.

10/14/2016 - TG Therapeutics, Inc. had its "buy" rating reiterated by analysts at Ladenburg Thalmann. The company plans to apply for approval by the first half of 2019, with results from the phase 3 trial expected by the second quarter of 2018.

10/06/2016 - Brean Capital began new coverage on TG Therapeutics, Inc. giving the company a "buy" rating. The Relative Volume value measured for Juno Therapeutics Inc. Needham & Company now has a strong-buy rating on the stock. The company has a 1 Year high price target of $31.09.

06/02/2015 - TG Therapeutics, Inc. had its "buy" rating reiterated by analysts at MLV & Co. There may be various price targets for a stock. (JUNO) to Neutral by settling a price target of $24 on 2/01/17.

The share price of TG Therapeutics, Inc. The stock traded with the volume of 2.82 Million shares in the last trading session. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -16.97% where SMA50 and SMA200 are 17.71% and 65.99% respectively. Raymond James Downgrades the stock to Market Perform on 12/06/16 with no specific Price Target. The variation in the four different studies include patients with hypercholesterolemia, which is high levels of cholesterol in the blood, those who can tolerate less than the lowest approved daily starting dose of statin, those who are considered "statin-intolerant", and those who are taking a low dose of statin with ezetimibe.

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize, hospital-based therapies capable of transforming treatment paradigms in the management of life-threatening neurological and other conditions. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. However, it could also mean that something is fundamentally wrong with the company.